Skip to main content
Top
Published in: Thrombosis Journal 1/2009

Open Access 01-12-2009 | Case report

Acute myocardial infarction and pulmonary embolism in a young man with pernicious anemia-induced severe hyperhomocysteinemia

Authors: Ayyash Melhem, Ankit Desai, Marion A Hofmann

Published in: Thrombosis Journal | Issue 1/2009

Login to get access

Abstract

A 27 year-old man who presented to the hospital with progressive lower extremity weakness, developed an acute ST elevation myocardial infarction on his second hospital day. Primary angioplasty to the left anterior descending coronary artery was performed. Due to persistent dyspnea, the patient underwent a diagnostic chest computed tomography which confirmed multiple small pulmonary emboli. Laboratory analysis revealed a megaloblastic anemia with a reduced vitamin B12 level and positive titers for antibodies against intrinsic factor, establishing a diagnosis of pernicious anemia. Screening for hypercoaguable markers documented an isolated severely elevated homocysteine levels (105 μmol/l). No other significant risk factors for coronary artery disease including a family history of premature atherosclerosis were identified. This case illustrates the importance of testing for hyperhomocysteinemia as part of a workup for atherothrombotic disease, especially in patients without other significant risk factors. The severity of hyperhomocysteinemia found in our patient is unusual for patients with vitamin B12 malabsorption and raises the question of whether the widely practiced folic acid fortification in the United States may mask or even worsen vitamin B12 deficiency over time, leading to more severe cases of vitamin B12 deficiency and hyperhomocysteinemia than seen in the past.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kang S, Wong P, Malinow M: Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992, 12: 279-98. 10.1146/annurev.nu.12.070192.001431CrossRefPubMed Kang S, Wong P, Malinow M: Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992, 12: 279-98. 10.1146/annurev.nu.12.070192.001431CrossRefPubMed
2.
go back to reference Welch G, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 1998, 338(15):1042-50. 10.1056/NEJM199804093381507CrossRefPubMed Welch G, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 1998, 338(15):1042-50. 10.1056/NEJM199804093381507CrossRefPubMed
3.
go back to reference Boushey CJ, Beresford SA, Omenn , Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274(13):1049-57. 10.1001/jama.274.13.1049CrossRefPubMed Boushey CJ, Beresford SA, Omenn , Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274(13):1049-57. 10.1001/jama.274.13.1049CrossRefPubMed
4.
go back to reference Wald D, Law M, Morris J: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325(7374):1202. 10.1136/bmj.325.7374.1202PubMedCentralCrossRefPubMed Wald D, Law M, Morris J: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325(7374):1202. 10.1136/bmj.325.7374.1202PubMedCentralCrossRefPubMed
5.
go back to reference Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288: 2015-2022. 10.1001/jama.288.16.2015CrossRef Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288: 2015-2022. 10.1001/jama.288.16.2015CrossRef
6.
go back to reference Bazzano LA, Reynolds K, Holder KN, He J: Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of rendomized controlled trials. JAMA 2006, 296(22):2720-6. Erratum in: JAMA. 2007 Mar 7;297(9):952 10.1001/jama.296.22.2720CrossRefPubMed Bazzano LA, Reynolds K, Holder KN, He J: Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of rendomized controlled trials. JAMA 2006, 296(22):2720-6. Erratum in: JAMA. 2007 Mar 7;297(9):952 10.1001/jama.296.22.2720CrossRefPubMed
7.
go back to reference The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354: 1567-1577. 10.1056/NEJMoa060900CrossRef The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354: 1567-1577. 10.1056/NEJMoa060900CrossRef
8.
go back to reference Toole J, Malinow M, Chambless L, et al.: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291: 565-575. 10.1001/jama.291.5.565CrossRefPubMed Toole J, Malinow M, Chambless L, et al.: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291: 565-575. 10.1001/jama.291.5.565CrossRefPubMed
9.
go back to reference Bønaa K, Njølstad I, Ueland P, et al.: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006, 354: 1578-1588. 10.1056/NEJMoa055227CrossRefPubMed Bønaa K, Njølstad I, Ueland P, et al.: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006, 354: 1578-1588. 10.1056/NEJMoa055227CrossRefPubMed
10.
go back to reference Joseph Loscalzo: Homocysteine trials – Clear Outcomes for Complex reasons. N Engl J Med 2006, 354(15):1629-32. 10.1056/NEJMe068060CrossRef Joseph Loscalzo: Homocysteine trials – Clear Outcomes for Complex reasons. N Engl J Med 2006, 354(15):1629-32. 10.1056/NEJMe068060CrossRef
11.
go back to reference McCully K: Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969, 56: 111-28.PubMedCentralPubMed McCully K: Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969, 56: 111-28.PubMedCentralPubMed
12.
go back to reference Keller C, Hoffman U, Loscalzo J: Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vascular Medicine 2002, 7(3):227-239. 10.1191/1358863x02vm428raCrossRefPubMed Keller C, Hoffman U, Loscalzo J: Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vascular Medicine 2002, 7(3):227-239. 10.1191/1358863x02vm428raCrossRefPubMed
13.
go back to reference Lentz S: Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005, 3(8):1646-54. 10.1111/j.1538-7836.2005.01364.xCrossRefPubMed Lentz S: Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005, 3(8):1646-54. 10.1111/j.1538-7836.2005.01364.xCrossRefPubMed
14.
go back to reference Dayal S, Lentz S: Murine models of hyperhomocysteinemia and their vascular phenotypes. Arterioscler Thromb Vasc Biol 2008, 28(9):1596-605. 10.1161/ATVBAHA.108.166421PubMedCentralCrossRefPubMed Dayal S, Lentz S: Murine models of hyperhomocysteinemia and their vascular phenotypes. Arterioscler Thromb Vasc Biol 2008, 28(9):1596-605. 10.1161/ATVBAHA.108.166421PubMedCentralCrossRefPubMed
15.
go back to reference Hofmann M, Lalla E, Gleason M, Kohl B, Wolf B, Kiesel W, Stern D, Schmidt A: Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001, 107(6):675-83. 10.1172/JCI10588PubMedCentralCrossRefPubMed Hofmann M, Lalla E, Gleason M, Kohl B, Wolf B, Kiesel W, Stern D, Schmidt A: Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001, 107(6):675-83. 10.1172/JCI10588PubMedCentralCrossRefPubMed
16.
go back to reference Lange H, Suryapranata H, De Luca G, Börner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, Dambrink JH: Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004, 350(26):2673-81. 10.1056/NEJMoa032845CrossRefPubMed Lange H, Suryapranata H, De Luca G, Börner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, Dambrink JH: Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004, 350(26):2673-81. 10.1056/NEJMoa032845CrossRefPubMed
17.
go back to reference Fernandez C, Yebra M, Ribera C, Toledo T, Martin M, Gomez P: Venous thromboembolism and hyperhomocysteinemia as first manifestation of pernicious anemia. Rev Clin Esp 2005, 205(10):489-92. 10.1157/13079763CrossRef Fernandez C, Yebra M, Ribera C, Toledo T, Martin M, Gomez P: Venous thromboembolism and hyperhomocysteinemia as first manifestation of pernicious anemia. Rev Clin Esp 2005, 205(10):489-92. 10.1157/13079763CrossRef
18.
go back to reference Limal N, Scheuermaier K, Tazi Z, Sene D, Piette J, Cacoub P: Hyperhomocysteinaemia, thrombosis and pernicious anaemia. Thromb Haemost 2006, 96(2):233-5.PubMed Limal N, Scheuermaier K, Tazi Z, Sene D, Piette J, Cacoub P: Hyperhomocysteinaemia, thrombosis and pernicious anaemia. Thromb Haemost 2006, 96(2):233-5.PubMed
19.
go back to reference Küpeli E, Cengiz C, Cila A, Karnak D: Hyperhomocysteinemia due to pernicious anemia leading to pulmonary thromboembolism in a heterozygous mutation carrier. Clin Appl Thromb Hemost 2008, 14(3):365-8. 10.1177/1076029607305101CrossRefPubMed Küpeli E, Cengiz C, Cila A, Karnak D: Hyperhomocysteinemia due to pernicious anemia leading to pulmonary thromboembolism in a heterozygous mutation carrier. Clin Appl Thromb Hemost 2008, 14(3):365-8. 10.1177/1076029607305101CrossRefPubMed
20.
go back to reference Rozen R: Genetic modulation of homocysteinemia. Semin Thromb Hemost 2000, 26: 255-261. 10.1055/s-2000-8470CrossRefPubMed Rozen R: Genetic modulation of homocysteinemia. Semin Thromb Hemost 2000, 26: 255-261. 10.1055/s-2000-8470CrossRefPubMed
21.
go back to reference Selhub J, Morris MS, Jaques PF: In vitamin b12 deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentration. PNAS 2007, 104(50):19995-20000. 10.1073/pnas.0709487104PubMedCentralCrossRefPubMed Selhub J, Morris MS, Jaques PF: In vitamin b12 deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentration. PNAS 2007, 104(50):19995-20000. 10.1073/pnas.0709487104PubMedCentralCrossRefPubMed
Metadata
Title
Acute myocardial infarction and pulmonary embolism in a young man with pernicious anemia-induced severe hyperhomocysteinemia
Authors
Ayyash Melhem
Ankit Desai
Marion A Hofmann
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2009
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/1477-9560-7-5

Other articles of this Issue 1/2009

Thrombosis Journal 1/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.